, /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: ) (the " ," " ," or " "), a leading medical cannabis company with operations in and , is experiencing accelerated growth in after the partial legalization, further to the Company's press release dated . Adjupharm GmbH's, IMC's German subsidiary (" " or " "), is supporting its growth by further bolstering its supply chain with an additional EU-GMP supplier, GlassHouse Botanics Inc.
(" "), headquartered in Whitewater, . The partial legalization of cannabis in , has potentially paved the way for tremendous category growth. With a population of over 83 million, has more than double the population of , which had a cannabis industry of about in 2023.
Until the social clubs are up and running, the only legal way to buy cannabis in is with a prescription, driving significant growth in the Medical Market. "While is impossible to say how big the opportunity in will be, if we assume a 1% penetration and an average spend of /month, the German market could have a potential run rate of approximately by the end of 2025," pointed out , CEO of IMC. IMC Germany spent 2023 preparing for the legalization by putting the processes in place to drive accelerated growth, while focusing on active cost management with the goal of achieving sustainable profitability.
In 2023, IMC Germany delivered +182% growth, outperforming the market by 162%, closing the year as a strong #6 among the cannabis distributors and ranked #1 in sales per SKU . "I am e.
